Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule analog of riboflavin pathway intermediates. It is a phosphonate derivative designed to mimic the natural substrate of lumazine synthase and acts as an inhibitor of this enzyme. Lumazine synthase is the penultimate enzyme in the biosynthesis of riboflavin (vitamin B₂). By inhibiting lumazine synthase activity in microorganisms (such as bacteria), this compound can potentially disrupt riboflavin biosynthesis and thus has been studied as an antibacterial agent or biochemical tool for probing flavin metabolism[4]. The compound was rationally designed using molecular modeling to fit into the active site of lumazine synthase and shows relatively potent inhibitory activity compared to other known inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(6-d-ribitylamino-2,4-dihydroxypyrimidin-5-yl)-1-pentyl-phosphonic acid.